A2 Refereed review article in a scientific journal
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape
Authors: Mazur Natalie I, Terstappen Jonne, Baral Ranju, Bardají Azucena, Beutels Philippe, Buchholz Ursula J, Cohen Cheryl, Crowe James E, Cutland Clare L, Eckert Linda, Feikin Daniel, Fitzpatrick Tiffany, Fong Youyi, Graham Barney S, Heikkinen Terho, Higgins Deborah, Hirve Siddhivinayak, Klugman Keith P, Kragten-Tabatabaie Leyla, Lemey Philippe, Libster Romina, Löwensteyn Yvette, Mejias Asuncion, Munoz Flor M, Munywoki Patrick K, Mwananyanda Lawrence, Nair Harish, Nunes Marta C, Ramilo Octavio, Richmond Peter, Ruckwardt Tracy J, Sande Charles, Srikantiah Padmini, Thacker Naveen, Waldstein Kody A, Weinberger Dan, Wildenbeest Joanne, Wiseman Dexter, Zar Heather J, Zambon Maria, Bont Louis
Publisher: Elsevier
Publication year: 2023
Journal: Lancet Infectious Diseases
Journal name in source: The Lancet. Infectious diseases
Journal acronym: Lancet Infect Dis
Volume: 23
Issue: 1
First page : e2
Last page: e21
ISSN: 1473-3099
eISSN: 1474-4457
DOI: https://doi.org/10.1016/S1473-3099(22)00291-2
Web address : https://doi.org/10.1016/S1473-3099(22)00291-2
Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. Nine candidates are in phase 3 clinical trials. Understanding the epitopes targeted by highly neutralising antibodies has resulted in a shift from empirical to rational and structure-based vaccine and monoclonal antibody design. An extended half-life monoclonal antibody for all infants is likely to be within 1 year of regulatory approval (from August, 2022) for high-income countries. Live-attenuated vaccines are in development for older infants (aged >6 months). Subunit vaccines are in late-stage trials for pregnant women to protect infants, whereas vector, subunit, and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of a respiratory syncytial virus vaccine globally. This review gives an overview of respiratory syncytial virus vaccines and monoclonal antibodies in clinical development highlighting different target populations, antigens, and trial results.
